HK1164050A1 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof - Google Patents

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Info

Publication number
HK1164050A1
HK1164050A1 HK12104614.4A HK12104614A HK1164050A1 HK 1164050 A1 HK1164050 A1 HK 1164050A1 HK 12104614 A HK12104614 A HK 12104614A HK 1164050 A1 HK1164050 A1 HK 1164050A1
Authority
HK
Hong Kong
Prior art keywords
methods
pharmaceutical compositions
substituted azoanthracene
azoanthracene derivatives
derivatives
Prior art date
Application number
HK12104614.4A
Other languages
English (en)
Chinese (zh)
Inventor
．米賈裡
．貝梅
．克裡森
．波裡塞蒂
．奎達
．桑索施
．邦德拉
．居澤爾
．亞拉岡塔
．戈希姆庫拉
．安德魯斯
．戴維斯
．約庫姆
．弗裡曼
Original Assignee
轉化技術製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 轉化技術製藥有限責任公司 filed Critical 轉化技術製藥有限責任公司
Publication of HK1164050A1 publication Critical patent/HK1164050A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12104614.4A 2009-03-30 2012-05-10 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof HK1164050A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1164050A1 true HK1164050A1 (en) 2012-09-21

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104614.4A HK1164050A1 (en) 2009-03-30 2012-05-10 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Country Status (18)

Country Link
US (3) US8383644B2 (ru)
EP (1) EP2413693B1 (ru)
JP (1) JP5755217B2 (ru)
KR (1) KR101732978B1 (ru)
CN (1) CN102378574B (ru)
AU (1) AU2010232750B2 (ru)
BR (1) BRPI1013579A2 (ru)
CA (1) CA2757084C (ru)
DK (1) DK2413693T3 (ru)
EA (1) EA023430B1 (ru)
ES (1) ES2553645T3 (ru)
HK (1) HK1164050A1 (ru)
IL (1) IL214822A (ru)
MA (1) MA33219B1 (ru)
MX (1) MX2011010347A (ru)
SG (1) SG174205A1 (ru)
TN (1) TN2011000437A1 (ru)
WO (1) WO2010114824A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33219B1 (fr) 2009-03-30 2012-04-02 Transtech Pharma Inc Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
AU2012326361B2 (en) 2011-10-17 2017-08-03 Biotheryx, Inc. Substituted biaryl alkyl amides
WO2014113357A1 (en) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
WO2016033105A1 (en) 2014-08-29 2016-03-03 The Board Of Regents Of The University Of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) * 2017-11-22 2019-05-31 第一三共株式会社 縮合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
KR20210005843A (ko) * 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
US20230174547A1 (en) * 2020-04-01 2023-06-08 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd PROCESS FOR PREPARING A FREE BASE OF GLP-1 RECEPTOR AGONIST
WO2021238965A1 (zh) 2020-05-28 2021-12-02 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN115667219A (zh) * 2020-05-28 2023-01-31 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
EP4159722A4 (en) 2020-05-28 2024-06-26 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST
WO2021242806A1 (en) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermediates and methods for preparing a glp-1 receptor agonist
CN115884969A (zh) 2020-09-01 2023-03-31 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
US20230382921A1 (en) * 2020-09-21 2023-11-30 Vtv Therapeutics Llc Amorphous Form of Isoquinoline Derivative
EP4225738A1 (en) * 2020-10-08 2023-08-16 Eli Lilly and Company 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022262143A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
IL309235A (en) 2021-06-24 2024-02-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd GLP-1 receptor agonist and its preparation and use
CN117897387A (zh) * 2021-09-03 2024-04-16 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
EP4410793A1 (en) 2021-09-28 2024-08-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Solid composition of glp-1 receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
KR20040016844A (ko) 2001-03-27 2004-02-25 액테리온 파마슈티칼 리미티드 유로텐신 ⅱ 수용체 길항제인1,2,3,4-테트라하이드로이소퀴놀린 유도체
DE60216952T2 (de) * 2001-10-19 2007-07-05 Transtech Pharma Inc. Beta-carbolin-derivate als ptp-inhibitoren
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
CN100432056C (zh) * 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (en) * 2007-03-26 2008-10-02 Neurogen Corporation Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones
DK2262364T3 (en) * 2008-03-07 2016-03-21 Vtv Therapeutics Llc Oxadiazoanthracenforbindelser for the treatment of diabetes
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
MA33219B1 (fr) 2009-03-30 2012-04-02 Transtech Pharma Inc Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
AU2010232750B2 (en) 2015-10-29
ES2553645T3 (es) 2015-12-10
EA201171197A8 (ru) 2014-10-30
EP2413693A4 (en) 2012-08-22
KR101732978B1 (ko) 2017-05-08
CN102378574B (zh) 2013-11-20
US20150148539A1 (en) 2015-05-28
BRPI1013579A2 (pt) 2020-11-03
IL214822A0 (en) 2011-11-30
AU2010232750A1 (en) 2011-09-08
CA2757084C (en) 2017-08-29
US9175003B2 (en) 2015-11-03
EP2413693B1 (en) 2015-09-09
KR20120006506A (ko) 2012-01-18
EA023430B1 (ru) 2016-06-30
IL214822A (en) 2016-08-31
JP5755217B2 (ja) 2015-07-29
SG174205A1 (en) 2011-10-28
EP2413693A1 (en) 2012-02-08
US8383644B2 (en) 2013-02-26
MA33219B1 (fr) 2012-04-02
CN102378574A (zh) 2012-03-14
WO2010114824A8 (en) 2011-10-06
TN2011000437A1 (en) 2013-03-27
MX2011010347A (es) 2011-11-29
EA201171197A1 (ru) 2012-04-30
DK2413693T3 (en) 2015-11-16
WO2010114824A1 (en) 2010-10-07
US20130096150A1 (en) 2013-04-18
US20110160198A1 (en) 2011-06-30
JP2012522060A (ja) 2012-09-20
CA2757084A1 (en) 2010-10-07
US8987295B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
HK1194071A1 (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
EP2562172A4 (en) SPHAELACTON DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION AND THEIR USE
EP2386553A4 (en) BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2536285A4 (en) SUBSTITUTED CONDENSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOUNDS AND USER METHOD THEREFOR
SI2281822T1 (sl) Novi derivati dihidroindolona, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
EP2504331A4 (en) COMPOUND, SOME NEW FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF PREPARATION AND USE
ZA201108458B (en) Nitrile derivatives and their pharmaceutical use and compositions
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2424533A4 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
PT2484661T (pt) Derivado de 2,3-di-hidro-1h-inden-2-il-ureia e sua aplicação farmacêutica
EP2452681A4 (en) SALTS OF 13A- (S-) DESOXYTYLPHORININE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
ZA201200165B (en) 2-amino-2phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same
HK1173335A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof